Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 94
Filter
1.
Paediatr Respir Rev ; 2024 Feb 16.
Article in English | MEDLINE | ID: mdl-38538377

ABSTRACT

The advent of next generation sequencing has rapidly challenged the paediatric respiratory physician's understanding of lung microbiology and the role of the lung microbiome in host health and disease. In particular, the role of "microbial key players" in paediatric respiratory disease is yet to be fully explained. Accurate profiling of the lung microbiome in children is challenging since the ability to obtain lower airway samples coupled with processing "low-biomass specimens" are both technically difficult. Many studies provide conflicting results. Early microbiota-host relationships may be predictive of the development of chronic respiratory disease but attempts to correlate lower airway microbiota in premature infants and risk of developing bronchopulmonary dysplasia (BPD) have produced mixed results. There are differences in lung microbiota in asthma and cystic fibrosis (CF). The increased abundance of oral taxa in the lungs may (or may not) promote disease processes in asthma and CF. In CF, correlation between microbiota diversity and respiratory decline is commonly observed. When one considers other pathogens beyond the bacterial kingdom, the contribution and interplay of fungi and viruses within the lung microbiome further increase complexity. Similarly, the interaction between microbial communities in different body sites, such as the gut-lung axis, and the influence of environmental factors, including diet, make the co-existence of host and microbes ever more complicated. Future, multi-omics approaches may help uncover novel microbiome-based biomarkers and therapeutic targets in respiratory disease and explain how we can live in harmony with our microbial companions.

2.
J Endocrinol ; 243(2): X1, 2019 09 16.
Article in English | MEDLINE | ID: mdl-32150359

ABSTRACT

The authors and journal apologise for an error in the above paper, which appeared in volume 199 part 2, pages 275­286. The error relates to Fig. 10, given on page 283.

3.
Prostate Cancer Prostatic Dis ; 19(3): 277-82, 2016 09.
Article in English | MEDLINE | ID: mdl-27136742

ABSTRACT

BACKGROUND: To date, there have been no published trials examining the impact of salvage radiation therapy (SRT) in the post-operative setting for prostate cancer (PCa). We conducted a retrospective, comparative study of post-operative radiation following radical prostatectomy (RP) for men with pT3 disease or positive margins (adverse pathological features, APF). METHODS: 422 PCa men treated at four institutions with RP and having APF were analyzed with a primary end point of metastasis. Adjuvant radiation treatment (ART, n=111), minimal residual disease (MRD) SRT (n=70) and SRT (n=83) were defined by PSA levels of <0.2, 0.2-0.49 and ⩾0.5 ng ml(-1), respectively, before radiation therapy (RT) initiation. Remaining 157 men who did not receive additional therapy before metastasis formed the no RT arm. Clinical-genomic risk was assessed by Cancer of the Prostate Risk Assessment Post-Surgical (CAPRA-S) and Decipher. Cox regression was used to evaluate the impact of treatment on outcome. RESULTS: During the study follow-up, 37 men developed metastasis with a median follow-up of 8 years. Both CAPRA-S and Decipher had independent predictive value on multivariable analysis for metastasis (P<0.05). Adjusting for clinical-genomic risk, SRT and no RT had hazard ratios of 4.31 (95% confidence interval, 1.20-15.47) and 5.42 (95% confidence interval, 1.59-18.44) for metastasis compared with ART, respectively. No significant difference was observed between MRD-SRT and ART (P=0.28). Men with low-to-intermediate CAPRA-S and low Decipher value have a low rate of metastatic events regardless of treatment selection. In contrast, men with high CAPRA-S and Decipher benefit from ART, however the cumulative incidence of metastasis remains high. CONCLUSIONS: The decision as to the timing and need for additional local therapy following RP is nuanced and requires providers and patients to balance risks of morbidity with improved oncological outcomes. Post-RP treatment can be safely avoided for men who are low risk by clinical-genomic risk, whereas those at high risk should favor enrollment in clinical trials.


Subject(s)
Prostatic Neoplasms/radiotherapy , Aged , Biomarkers, Tumor , Cohort Studies , Humans , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Postoperative Period , Prognosis , Proportional Hazards Models , Prostatectomy , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/surgery , Radiotherapy, Adjuvant
4.
Sci Rep ; 5: 10740, 2015 Jun 01.
Article in English | MEDLINE | ID: mdl-26030284

ABSTRACT

The pancreatic islet of Langerhans is composed of endocrine cells producing and releasing hormones from secretory granules in response to various stimuli for maintenance of blood glucose homeostasis. In order to adapt to a variation in functional demands, these islets are capable of modulating their hormone secretion by increasing the number of endocrine cells as well as the functional response of individual cells. A failure in adaptive mechanisms will lead to inadequate blood glucose regulation and thereby to the development of diabetes. It is therefore necessary to develop tools for the assessment of both pancreatic islet mass and function, with the aim of understanding cellular regulatory mechanisms and factors guiding islet plasticity. Although most of the existing techniques rely on the use of artificial indicators, we present an imaging methodology based on intrinsic optical properties originating from mature insulin secretory granules within endocrine cells that reveals both pancreatic islet mass and function. We demonstrate the advantage of using this imaging strategy by monitoring in vivo scattering signal from pancreatic islets engrafted into the anterior chamber of the mouse eye, and how this versatile and noninvasive methodology permits the characterization of islet morphology and plasticity as well as hormone secretory status.


Subject(s)
Dynamic Light Scattering , Islets of Langerhans/cytology , Islets of Langerhans/metabolism , Animals , Islets of Langerhans/growth & development , Islets of Langerhans/ultrastructure , Mice , Organ Size , Pancreatic Hormones/metabolism , Rats
5.
Annu Int Conf IEEE Eng Med Biol Soc ; 2015: 3663-6, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26737087

ABSTRACT

This paper presents the experimental evaluation of a coordinated control system for a robot and robot-driven shape memory alloy (SMA) actuated smart flexible needle capable of following a curved path for percutaneous intervention. The robot driving the needle is considered the outer loop and the non-linear SMA actuated flexible needle system comprises the inner loop. The two feedback control loops are coordinated in such a way that the robot drives the needle while monitoring the needle's actual deflection against a preplanned ideal trajectory, so that the needle tip reaches the target location within an acceptable accuracy. In air and in water experimental results are presented to validate the ability of the proposed coordinated controller to track the overall desired trajectory which includes the combined trajectory of the robot driver and the needle.


Subject(s)
Alloys , Feedback , Medicine/instrumentation , Needles , Robotics/instrumentation , Administration, Cutaneous , Biopsy , Brachytherapy
6.
Br J Cancer ; 111(7): 1305-9, 2014 Sep 23.
Article in English | MEDLINE | ID: mdl-25117813

ABSTRACT

BACKGROUND: The clinical development of new drugs with radiation appears to be limited. We hypothesised that phase I clinical trials with radiation therapy (RT) are initiated too late into a new drug's lifetime, impeding the ability to complete RT-drug development programmes before patent expiration. METHODS: We identified novel drug-radiation phase I combination trials performed between 1980 and 2012 within the PubMed and ClinicalTrials.gov databases. Data gathered for each drug included: date the initial phase I trial with/without RT was opened/published, date of the published positive phase III trials, and patent expiration dates. Lag time was defined as the interval between opening of the phase I trial without RT and the opening of the phase I with RT. Linear regression was used to model how the lag time has changed over time. RESULTS: The median lag time was 6 years. The initial phase I trial with RT was typically published 2 years after the first published positive phase III trial and 11 years before patent expiration. Using a best-fit linear model, lag time decreased from 10 years for phase I trials published in 1990 to 5 years in 2005 (slope significantly non-zero, P<0.001). CONCLUSIONS: Clinical drug development with RT commences late in the life cycle of anti-cancer agents. Taking into account the additional time required for late-phase clinical trials, the delay in initiating clinical testing of drug-RT combinations discourages drug companies from further pursuing RT-based development. Encouragingly, lag time appears to be decreasing. Further reduction in lag time may accelerate RT-based drug development, potentially improving patient outcomes.


Subject(s)
Antineoplastic Agents/therapeutic use , Chemoradiotherapy , Neoplasms/therapy , Clinical Trials, Phase I as Topic , Humans , Quality Improvement , Time Factors
7.
Br J Cancer ; 110(6): 1472-80, 2014 Mar 18.
Article in English | MEDLINE | ID: mdl-24556625

ABSTRACT

BACKGROUND: Monoclonal antibody (mAb) therapy for the treatment of solid and haematologic malignancies has shown poor response rates as a monotherapy. Furthermore, its use is limited to tumours expressing certain molecular targets. It has been shown that single-dose radiation can induce immunogenic modulation that is characterised by cell-surface phenotypic changes leading to augmented tumour cell/cytotoxic T-cell interaction. METHODS: We examined radiation's ability to upregulate mAb therapy targets. We also used radiation to sensitise tumour cells to antibody-dependent cell-mediated cytotoxicity (ADCC). RESULTS: Radiation significantly increased cell-surface and total protein expression of mAb targets HER2, EGFR, and CD20. Focusing on HER2, targeted by trastuzumab, we observed significant upregulation of HER2 following radiation of 3 out of 3 breast cancer cell lines, one of which was triple negative, as well as in residential stem-cell populations. HER2 upregulation was sustained up to 96 h following radiation exposure and was largely dependent on intracellular reactive oxygen species. Improved ADCC and sensitisation to the antiproliferative effects of trastuzumab demonstrated the functional significance of radiation-induced HER2 upregulation. CONCLUSIONS: We show that single-dose radiation enhances mAb therapy. These findings highlight a mechanism for combining radiation with immunotherapy and expand the patient population that can be treated with targeted therapy.


Subject(s)
Antibodies, Monoclonal/pharmacology , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Antibodies, Monoclonal, Humanized/pharmacology , Antibody-Dependent Cell Cytotoxicity/radiation effects , Antigens, CD20/biosynthesis , Antigens, CD20/immunology , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Cell Culture Techniques , Cell Line, Tumor , Combined Modality Therapy , ErbB Receptors/biosynthesis , ErbB Receptors/immunology , Female , Humans , MCF-7 Cells , Molecular Targeted Therapy/methods , Protein Biosynthesis/radiation effects , Reactive Oxygen Species/metabolism , Receptor, ErbB-2/biosynthesis , Receptor, ErbB-2/immunology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/radiation effects , Trastuzumab , Up-Regulation/radiation effects
8.
Prostate Cancer Prostatic Dis ; 16(2): 181-6, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23399780

ABSTRACT

BACKGROUND: The worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development. METHODS: This study consisted of 11 541 men with coronary heart disease screened to participate in a secondary cardiac prevention trial. MS was defined according to modified NCEP/ATP III criteria. Multivariable regression analysis accounting for competing risks was performed using a modified Cox proportional hazard model in order to assess the association between diabetes, the MS and the subsequent development of prostate cancer. RESULTS: At baseline, subjects were classified into one of the four groups: (1) 6119 (53%) with neither diabetic mellitus nor MS, (2) 3376 (29%) with the MS but without diabetes, (3) 560 (5%) with diabetes mellitus but without MS and (4) 1486 (13%) with both conditions. Median follow-up was 12.7 years (range 0-15.7 years). During follow-up, 459 new cases of prostate cancer were recorded. The age-adjusted hazard ratio (HR) for prostate cancer was reduced in diabetic patients compared with those without diabetes, 0.54 and 95% confidence interval of 0.40-0.73. No significant association was noted between the presence of MS and prostate cancer development. On multivariate analysis, diabetes mellitus continued to protect against the development of prostate cancer, this was more pronounced in the absence of MS (HR=0.43, P=0.01 for diabetes in the absence of MS; HR=0.64, P=0.08 in the presence of MS). CONCLUSIONS: The results of this study indicate an inverse association between type 2 diabetes mellitus and prostate cancer risk.


Subject(s)
Coronary Disease/complications , Diabetes Mellitus, Type 2/complications , Metabolic Syndrome/complications , Prostatic Neoplasms/etiology , Aged , Coronary Disease/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Humans , Incidence , Male , Metabolic Syndrome/epidemiology , Middle Aged , Proportional Hazards Models , Prostatic Neoplasms/epidemiology , Randomized Controlled Trials as Topic , Risk
9.
Med Phys ; 39(11): 6957-67, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23127089

ABSTRACT

PURPOSE: This study presents the implementation and experimental results of a novel technique for 4D tumor tracking using a commercially available and commonly used treatment couch and evaluates the tumor tracking accuracy in clinical settings. METHODS: Commercially available couch is capable of positioning the patient accurately; however, currently there is no provision for compensating physiological movement using the treatment couch in real-time. In this paper, a real-time couch tracking control technique is presented together with experimental results in tumor motion compensation in four dimensions (superior-inferior, lateral, anterior-posterior, and time). To implement real-time couch motion for tracking, a novel control system for the treatment couch was developed. The primary functional requirements for this novel technique were: (a) the treatment couch should maintain all previous∕normal features for patient setup and positioning, (b) the new control system should be used as a parallel system when tumor tracking would be deployed, and (c) tracking could be performed in a single direction and∕or concurrently in all three directions of the couch motion (longitudinal, lateral, and vertical). To the authors' best knowledge, the implementation of such technique to a regular treatment couch for tumor tracking has not been reported so far. To evaluate the performance of the tracking couch, we investigated the mechanical characteristics of the system such as system positioning resolution, repeatability, accuracy, and tracking performance. Performance of the tracking system was evaluated using dosimetric test as an endpoint. To investigate the accuracy of real-time tracking in the clinical setting, the existing clinical treatment couch was replaced with our experimental couch and the linear accelerator was used to deliver 3D conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) treatment plans with and without tracking. The results of radiation dose distribution from these two sets of experiments were compared and presented here. RESULTS: The mechanical accuracies were 0.12, 0.14, and 0.18 mm in X, Y, and Z directions. The repeatability of the desired motion was within ±0.2 mm. The differences of central axis dose between the 3D-CRT stationary plan and two tracking plans with different motion trajectories were 0.21% and 1.19%. The absolute dose differences of both 3D tracking plans comparing to the stationary plan were 1.09% and 1.20%. Comparing the stationary IMRT plan with the tracking IMRT plan, it was observed that the central axis dose difference was -0.87% and the absolute difference of both IMRT plans was 0.55%. CONCLUSIONS: The experimental results revealed that the treatment couch could be successfully used for real-time tumor tracking with a high level of accuracy. It was demonstrated that 4D tumor tracking was feasible using existing couch with implementation of appropriate tracking methodology and with modifications in the control system.


Subject(s)
Neoplasms/radiotherapy , Radiotherapy, Computer-Assisted/instrumentation , Robotics , Mechanical Phenomena , Movement , Phantoms, Imaging , Radiometry
10.
Pharmacogenomics J ; 12(5): 395-403, 2012 Oct.
Article in English | MEDLINE | ID: mdl-21625252

ABSTRACT

The aim of this study is to validate the prognostic and predictive value of the non-synonymous cytidine deaminase (CDA) Lys²7Gln polymorphism for hematological toxicity and survival using a randomized phase III adjuvant trial (Radiation Therapy Oncology Group (RTOG) 9704) in pancreatic cancer in which one treatment arm received gemcitabine. CDA is involved in gemcitabine inactivation, and there is conflicting data on the role of the non-synonymous CDA Lys²7Gln polymorphism in predicting toxicity and survival in cancer patients treated with gemcitabine. RTOG 9704 randomized 538 patients after pancreatic resection to receive radiotherapy with either 5-fluorouracil (5-FU) or gemcitabine. CDA Lys²7Gln polymorphism genotype was analyzed. We tested an association between CDA single-nucleotide polymorphism genotype and the survival outcome by the Cox proportional hazard model adjusting for other covariates, as well as toxicity by the logistic regression model. There is statistically significant more severe hematological toxicity in patients treated with gemcitabine with either the homozygote wild-type genotype (Lys/Lys) alone (odds ratio (OR)=0.06, P=0.01), or in combination with the heterozygote (Lys/Gln; OR=0.14, P=0.03) when compared with homozygote variant genotype (Gln/Gln) when adjusted for other covariates. This was not seen in the non-gemcitabine treated arm. There are no genotype differences with respect to survival outcome. In conclusion, in this prospective randomized adjuvant study of patients with pancreatic cancer, the CDA Lys²7Gln polymorphism is validated as a predictive marker of gemcitabine hematological toxicity, but not with treatment response or survival.


Subject(s)
Cytidine Deaminase/genetics , Deoxycytidine/analogs & derivatives , Pancreatic Neoplasms/drug therapy , Polymorphism, Single Nucleotide/genetics , Adult , Aged , Aged, 80 and over , Biomarkers, Pharmacological , Cytidine Deaminase/metabolism , Deoxycytidine/administration & dosage , Deoxycytidine/toxicity , Disease-Free Survival , Female , Fluorouracil/administration & dosage , Fluorouracil/toxicity , Humans , Male , Middle Aged , Neoplasm Staging , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/surgery , Gemcitabine
11.
Ann Oncol ; 23(3): 701-706, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21659666

ABSTRACT

BACKGROUND: This analysis was carried out to evaluate the cost-effectiveness of adjuvant radiation therapy (ART) versus observation, using a decision analysis model based primarily upon the published results of the Southwest Oncology Group prospective trial (SWOG 8794). PATIENTS AND METHODS: A decision analysis model was designed to compare ART versus observation over a 10-year time horizon. Probabilities of treatment success, utilization of salvage treatments, and rates of adverse events were taken from published results of SWOG 8794. Cost inputs were based on 2010 Medicare reimbursement rates. Primary outcome measure was incremental cost per prostate-specific antigen (PSA) success (i.e. serum PSA level <0.4 ng/ml). RESULTS: ART results in a higher PSA success rate than observation with probability of 0.43 versus 0.22. The mean incremental cost per patient for ART versus observation was $6023. The mean incremental cost-effectiveness ratio was $26,983 over the 10-year period. CONCLUSIONS: ART appears cost effective compared with observation based upon this decision analysis model. Future research should consider more costly radiation therapy (RT) approaches, such as intensity-modulated RT, and should evaluate the cost-effectiveness of ART versus early salvage RT.


Subject(s)
Prostatic Neoplasms/economics , Prostatic Neoplasms/radiotherapy , Cost-Benefit Analysis , Decision Support Techniques , Humans , Male , Prostatectomy , Prostatic Neoplasms/surgery , Radiotherapy, Adjuvant
12.
Br J Cancer ; 104(9): 1365-71, 2011 Apr 26.
Article in English | MEDLINE | ID: mdl-21487410

ABSTRACT

BACKGROUND: Patients with high-grade gliomas are treated with surgery followed by chemoradiation. The risk factors and implications of neurological side effects are not known. METHODS: Acute and late ≥ grade 3 neurological toxicities (NTs) were analysed among 2761 patients from 14 RTOG trials accrued from 1983 to 2003. The association between acute and late toxicity was analysed using a stepwise logistic regression model. The association between the occurrence of acute NT and survival was analysed as an independent variable. RESULTS: There were 2610 analysable patients (86% glioblastoma, 10% anaplastic astrocytoma). All received a systemic agent during radiation (83% chemotherapy, 17% biological agents). Median radiation dose was 60 Gy. There were 182 acute and 83 late NT events. On univariate analysis, older age, poor performance status, aggressive surgery, pre-existing neurological dysfunction, poor mental status and twice-daily radiation were associated with increased acute NT. In a stepwise logistic regression model the occurrence of acute NT was significantly associated with late NT (OR=2.40; 95% CI=1.2-4.8; P=0.014). The occurrence of acute NT predicted poorer overall survival, independent of recursive partitioning analysis class (median 7.8 vs 11.8 months). INTERPRETATION: Acute NT is significantly associated with both late NT and overall survival.


Subject(s)
Antineoplastic Agents/adverse effects , Dacarbazine/analogs & derivatives , Glioma/pathology , Glioma/therapy , Supratentorial Neoplasms/pathology , Supratentorial Neoplasms/therapy , Acute Disease , Adult , Aged , Analysis of Variance , Antineoplastic Agents/administration & dosage , Chemotherapy, Adjuvant/adverse effects , Dacarbazine/administration & dosage , Dacarbazine/adverse effects , Dose Fractionation, Radiation , Female , Glioma/drug therapy , Glioma/radiotherapy , Glioma/surgery , Humans , Incidence , Logistic Models , Male , Middle Aged , Radiotherapy, Adjuvant/adverse effects , Retrospective Studies , Risk Factors , Supratentorial Neoplasms/drug therapy , Supratentorial Neoplasms/radiotherapy , Supratentorial Neoplasms/surgery , Survival Analysis , Temozolomide , Time Factors
13.
Oncogene ; 30(4): 457-70, 2011 Jan 27.
Article in English | MEDLINE | ID: mdl-20856200

ABSTRACT

The PI3K/AKT signaling pathway is aberrant in a wide variety of cancers. Downstream effectors of AKT are involved in survival, growth and metabolic-related pathways. In contrast, contradictory data relating to AKT effects on cell motility and invasion, crucial prometastatic processes, have been reported pointing to a potential cell type and isoform type-specific AKT-driven function. By implication, study of AKT signaling should optimally be conducted in an appropriate intracellular environment. Prognosis in soft-tissue sarcoma (STS), the aggressive malignancies of mesenchymal origin, is poor, reflecting our modest ability to control metastasis, an effort hampered by lack of insight into molecular mechanisms driving STS progression and dissemination. We examined the impact of the cancer progression-relevant AKT pathway on the mesenchymal tumor cell internal milieu. We demonstrate that AKT1 activation induces STS cell motility and invasiveness at least partially through a novel interaction with the intermediate filament vimentin (Vim). The binding of AKT (tail region) to Vim (head region) results in Vim Ser39 phosphorylation enhancing the ability of Vim to induce motility and invasion while protecting Vim from caspase-induced proteolysis. Moreover, vimentin phosphorylation was shown to enhance tumor and metastasis growth in vivo. Insights into this mesenchymal-related molecular mechanism may facilitate the development of critically lacking therapeutic options for these devastating malignancies.


Subject(s)
Cell Movement , Mesoderm/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Sarcoma/metabolism , Soft Tissue Neoplasms/metabolism , Vimentin/metabolism , Animals , Blotting, Western , Cell Line, Tumor , Fluorescent Antibody Technique , Humans , Immunoprecipitation , Mesoderm/pathology , Mice , Mice, SCID , Neoplasm Invasiveness/genetics , Neoplasm Invasiveness/pathology , Proto-Oncogene Proteins c-akt/genetics , Sarcoma/genetics , Sarcoma/pathology , Signal Transduction/physiology , Soft Tissue Neoplasms/genetics , Soft Tissue Neoplasms/pathology , Transfection
14.
Int J Obes (Lond) ; 34(8): 1333-40, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20231847

ABSTRACT

OBJECTIVE: Neuropeptides NPFF and NPSF are involved in pain control, acting through the G-protein coupled receptors (GPR)74 (high affinity for NPFF) and GPR147 (equal affinity for NPFF and NPSF). GPR74 also inhibits catecholamine-induced adipocyte lipolysis and regulates fat mass in humans. The aim of this study was to compare the effects of NPFF and NPSF on noradrenaline-induced lipolysis and to determine the expression of their receptors in human fat cells. DESIGN: Adipose tissue was obtained during surgery. Adipocytes were prepared and kept in primary culture. Lipolysis, protein expression and gene expression were determined. RESULTS: NPFF counteracted noradrenaline-induced lipolysis, which was more marked after 48 h than after 4 h exposure and was solely attributed to inhibition of beta-adrenoceptor signalling. NPSF counteracted noradrenaline-induced lipolysis maximally after 4 h of exposure, which was attributed to a combination of inhibition of beta-adrenoceptor signalling and decreased activation of the protein kinase-A hormone sensitive lipase complex by cyclic AMP. Both neuropeptides were effective in nanomolar concentrations. NPFF and NPSF had no effects on the expression of genes involved in catecholamine signal transduction. Both GPR74 and GPR147 were expressed at the protein level in fat cells from various adipose regions. GPR74 mRNA levels were higher in adipose tissue from obese as compared with non-obese subjects. High gene expression of either receptor correlated with low noradrenaline-induced lipolysis (P<0.05). CONCLUSIONS: Pain controlling neuropeptides NPFF and NPSF may be important for the regulation of lipolysis in man probably acting through GPR74 and GPR147. At low concentrations they inhibit catecholamine-induced lipolysis through rapid and long-term post-transcriptional effects at several steps in adrenoceptor signalling in fat cells.


Subject(s)
Adipocytes/drug effects , Adipose Tissue/metabolism , Lipolysis/drug effects , Neuropeptides/pharmacology , Oligopeptides/pharmacology , Adipocytes/physiology , Adult , Female , Humans , Lipolysis/physiology , Male , Middle Aged , Neuropeptides/metabolism , Oligopeptides/metabolism , Receptors, Neuropeptide/physiology , Young Adult
15.
Horm Metab Res ; 41(5): 350-5, 2009 May.
Article in English | MEDLINE | ID: mdl-19204889

ABSTRACT

Catecholamine-induced lipolysis is elevated in omental as compared to subcutaneous adipocytes due to primary differences between the two cell types (i.e., they have different progenitor cells). Whether there is regional variation in atrial natriuretic peptide (ANP)-induced lipolysis is unknown. We studied whether beta-adrenoceptor signaling to lipolysis and ANP-induced lipolysis are involved in the primary differences in lipolysis. In vitro experiments on differentiated preadipocytes from human subcutaneous and omental adipose tissue were performed. The cells were kept in culture for a relative long duration, so any influence of local environment and circulation in the various adipose tissue depots could be excluded. Using beta1-, beta2-, and beta3-adenoceptor agonists, lipolysis was found to be significantly higher in omental as compared to subcutaneous differentiated preadipocytes. Forskolin and dibutyryl cAMP, which act at post-adrenoceptor levels, did not show any regional difference. There was no regional difference in ANP-induced lipolysis. Gene expression of beta1- and beta3-adrenoceptors was higher and beta2-adrenoceptor expression was lower in the omental cells. Omental fat cells have an increased beta-adrenoceptor-mediated lipolysis principally due to primary differences in the early event that couples beta-adrenoceptor subtypes to G-proteins. ANP-induced lipolysis is not subject to primary regional variation.


Subject(s)
Adipocytes/cytology , Cell Differentiation , Lipolysis , Omentum/metabolism , Subcutaneous Fat/metabolism , Adipocytes/metabolism , Adult , Cells, Cultured , Female , Humans , Middle Aged , Omentum/cytology , Receptors, Adrenergic, beta/genetics , Receptors, Adrenergic, beta/metabolism , Signal Transduction , Subcutaneous Fat/cytology
16.
J Endocrinol ; 199(2): X1, 2008 11.
Article in English | MEDLINE | ID: mdl-18757549

ABSTRACT

The aim of this study was to validate the role of estrogen receptor alpha (ERalpha) signaling in the regulation of glucose metabolism, and to compare the molecular events upon treatment with the ERalpha-selective agonist propyl pyrazole triol (PPT) or 17beta-estradiol (E(2)) in ob/ob mice. Female ob/ob mice were treated with PPT, E(2) or vehicle for 7 or 30 days. Intraperitoneal glucose and insulin tolerance tests were performed, and insulin secretion was determined from isolated islets. Glucose uptake was assayed in isolated skeletal muscle and adipocytes. Gene expression profiling in the liver was performed using Affymetrix microarrays, and the expression of selected genes was studied by real-time PCR analysis. PPT and E(2) treatment improved glucose tolerance and insulin sensitivity. Fasting blood glucose levels decreased after 30 days of PPT and E(2) treatment. However, PPT and E(2) had no effect on insulin secretion from isolated islets. Basal and insulin-stimulated glucose uptake in skeletal muscle and adipose tissue were similar in PPT and vehicle-treated ob/ob mice. Hepatic lipid content was decreased after E(2) treatment. In the liver, treatment with E(2) and PPT increased and decreased the respective expression levels of the transcription factor signal transducer and activator of transcription 3, and of glucose-6-phosphatase. In summary, our data demonstrate that PPT exerts anti-diabetic effects, and these effects are mediated via ERalpha.


Subject(s)
Estrogen Receptor alpha/agonists , Glucose Intolerance/drug therapy , Pyrazoles/pharmacology , Adipose Tissue/metabolism , Animals , Blotting, Western , Body Weight/drug effects , Computational Biology , Estradiol/pharmacology , Female , Glucose Tolerance Test , Glucose-6-Phosphatase/genetics , In Vitro Techniques , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Liver/metabolism , Magnetic Resonance Spectroscopy , Mice , Mice, Obese , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Oligonucleotide Array Sequence Analysis , Phenols , Polymerase Chain Reaction
17.
Vector Borne Zoonotic Dis ; 7(3): 457-60, 2007.
Article in English | MEDLINE | ID: mdl-17767407

ABSTRACT

Periodic wildlife rabies epizootics occur in Arctic regions. The original sources of these outbreaks are rarely identified. In 1980, a wildlife epizootic of rabies occurred on the previously rabies-free Svalbard Islands, Norway. After this outbreak of rabies in the arctic fox population (Alopex lagopus), only single cases have been reported from the Islands over the following two decades. Phylogenetic characterization of four viruses isolated from infected arctic foxes from Svalbard from three different time periods suggest that the source of these epizootics could have been migration of this species from the Russian mainland. Arctic fox migration has likely contributed to the establishment of another zoonotic disease, Echinococcus multilocularis, on Svalbard in recent years.


Subject(s)
Disease Outbreaks , Foxes/virology , Phylogeny , Rabies virus/classification , Rabies/epidemiology , Rabies/virology , Animals , Cell Line, Tumor , Mice , Molecular Sequence Data , Nucleoproteins/genetics , Rabies virus/genetics , Rabies virus/isolation & purification , Sequence Homology, Nucleic Acid , Svalbard/epidemiology
18.
Clin Pharmacol Ther ; 82(1): 70-80, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17495877

ABSTRACT

In vivo studies represent an essential step in drug development and currently rely largely on mice, yet limitations of mammalian models motivated the search for complementary vertebrate model systems. This review focuses on zebrafish, Danio rerio, as a facile model system to study human disease and drug responses. Zebrafish are particularly suited for this purpose because they represent a vertebrate species, their genome is sequenced, and a large number of synchronously developing, transparent embryos can be produced. Zebrafish embryos are permeable to drugs and can easily be manipulated using well-established genetic and molecular approaches. Here, we summarize recent work on drug discovery and toxicity in zebrafish embryos. In addition, we provide a synopsis of current efforts to establish disease models in zebrafish focusing on neoplasia. The results of these studies highlight the potential of zebrafish as a viable addition to established animal models by offering medium and, potentially, high throughput capabilities.


Subject(s)
Drug Design , Drug Evaluation, Preclinical/methods , Models, Animal , Toxicity Tests/methods , Zebrafish/embryology , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carcinogenicity Tests/methods , Carcinogens/toxicity , Cell Transformation, Neoplastic/drug effects , DNA Damage , Embryo, Nonmammalian/drug effects , Embryo, Nonmammalian/pathology , Gene Expression Regulation, Developmental/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mutagenicity Tests/methods , Mutagens/toxicity , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/embryology , Reproducibility of Results , Zebrafish/genetics
19.
Horm Metab Res ; 39(4): 282-7, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17447167

ABSTRACT

The ability of catecholamines to maximally stimulate adipocyte lipolysis (lipolytic capacity) is decreased in obesity. It is not known whether the lipolytic capacity is determined by the ability of adipocytes to differentiate. The aim of the study was to investigate if lipolytic capacity is related to preadipocyte differentiation and if the latter can predict lipolysis in mature adipocytes. IN VITRO experiments were performed on differentiating preadipocytes and isolated mature adipocytes from human subcutaneous adipose tissue. In preadipocytes, noradrenaline-induced lipolysis increased significantly until terminal differentiation (day 12). However, changes in the expression of genes involved in lipolysis (hormone sensitive lipase, adipocyte triglyceride lipase, the alpha2-and beta1-adrenoceptors, perilipin, and fatty acid binding protein) reached a plateau much earlier during differentiation (day 8). A significant positive correlation between lipolysis in differentiated preadipocytes and mature adipocytes was observed for noradrenaline (r=0.5, p<0.01). The late differentiation capacity of preadipocytes measured as glycerol-3-phosphate dehydrogenase activity was positively correlated with noradrenaline-induced lipolysis in preadipocytes (r=0.51, p<0.005) and mature fat cells (r=0.35, p<0.05). In conclusion, intrinsic properties related to terminal differentiation determine the ability of catecholamines to maximally stimulate lipolysis in fat cells. The inability to undergo full differentiation might in part explain the low lipolytic capacity of fat cells among the obese.


Subject(s)
Adipocytes/metabolism , Cell Differentiation/physiology , Lipolysis/physiology , Stem Cells/physiology , Adipocytes/drug effects , Adult , Biomarkers , Body Mass Index , Cell Differentiation/drug effects , Culture Media, Serum-Free , Glycerolphosphate Dehydrogenase/biosynthesis , Glycerolphosphate Dehydrogenase/metabolism , Humans , Lipolysis/drug effects , Male , Neurosecretory Systems/cytology , Neurosecretory Systems/physiology , Norepinephrine/pharmacology , PPAR gamma/biosynthesis , PPAR gamma/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Stem Cells/drug effects
20.
Int J Obes (Lond) ; 29(12): 1413-21, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16077714

ABSTRACT

OBJECTIVE: Human adipocytes can be obtained in vitro by differentiation of human preadipocytes or mesenchymal stem cells (hMSC). Although functionally similar to freshly isolated cells, no detailed comparison of the different cell types has been performed. The antilipolytic alpha2A-adrenoceptor (AR) and the cAMP-degrading enzyme Phosphodiesterase-3B (PDE3B) have been implicated in the fine-tuning of lipolysis but little is known regarding their role in human adipocytes nor whether their expression and/or function differs in fat cells from different precursors. METHODS: The effects of alpha2A-AR and PDE3B inhibition in mature adipocytes was determined and compared to that in differentiated preadipocytes and hMSC-derived fat cells. Gene expression was determined by real-time PCR and protein expression by Western blot. RESULTS: Noradrenaline (NA) stimulated lipolysis in preadipocytes and mature adipocytes but markedly reduced lipolysis in differentiated hMSC derived-adipocytes. This was due to a potent stimulation of alpha2A-AR since co-incubation with NA and the alpha2-AR-inhibitor yohimbine restored NA-induced lipolysis. The order of Yohimbine response was hMSC>preadipocytes>mature adipocytes. Although alpha2-AR mRNA expression was highest in mature adipocytes there was no difference in alpha2A-AR protein levels between the cell types. In contrast, Galphai2 mRNA and protein expression was significantly higher in MSC-derived adipocytes, suggesting that differences in the response to alpha2A-AR inhibition reside at the postreceptor level. Incubation with the cAMP-analog 8-bromo(8b) cAMP increased lipolysis in hMSC-derived fat cells while co-incubation with the PDE3-specific inhibitor OPC3911 did not alter the lipolytic effect. In contrast, OPC3911 increased 8bcAMP-induced lipolysis significantly in preadipocytes and mature adipocytes. The response to PDE3B inhibition was; mature adipocytes>preadipocytes>hMSC a finding that correlated significantly with both PDE3B mRNA expression and enzymatic activity. CONCLUSION: Although differentiated adipocytes of different origins display similar functional characteristics there are important differences in the regulation of lipolysis with a marked alpha2A-AR and less pronounced PDE3B effect in fat cells from MSCs.


Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/metabolism , Adipocytes/metabolism , Cell Differentiation/physiology , Lipolysis/drug effects , Mesenchymal Stem Cells/metabolism , Receptors, Adrenergic, alpha-2/metabolism , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Adipocytes/cytology , Adipocytes/drug effects , Adult , Blotting, Western , Cyclic AMP/metabolism , Cyclic Nucleotide Phosphodiesterases, Type 3 , Female , Humans , Mesenchymal Stem Cells/cytology , Middle Aged , Polymerase Chain Reaction , Quinolones/pharmacology , RNA, Messenger/metabolism , Yohimbine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...